



# Supplemental Figure S6


**A**




**B**




**D**




**F**




**I**




**C**




**E**




**G**



**H**



**J**



**Supplemental Figure S6: Characterization of ELAVL1 targets and global influence on the transcriptional landscape.** (A) GSEA plots showing LSC and myeloid signature enrichments in the *Elavl1*-knockout RN2c transcriptome. (B) Western blot of *Elavl1* in murine *Lin*<sup>-</sup>, bcCML and MLL-AF9 cells. (C) Immunofluorescent microscopy of ELAVL1, nuclear marker (DAPI) and cytoplasmic marker (G3BP1). Scale bars of 20 $\mu$ M are shown. (D) Summary of intersection of transcripts bound (grey) and differentially expressed (up=red, down=blue,  $p$ . adj <0.05) upon *Elavl1*-deletion. (E) qPCR of ELAVL1 targets in RN2c 24-72h post-treatment with 2.2 $\mu$ M MS-444 or vehicle control (DMSO). (F) Expression distribution of bound and not bound transcripts in *Elavl1*-knockout RN2c cells. (G) GO term enrichment analysis for transcripts both bound and differentially expressed ( $p$  adj <0.05) upon *Elavl1*-deletion. (H) Volcano plot of differential exon skipping in ELAVL1 knockout RN2c cells, >15% inclusion and exclusion at FDR<0.1 indicated in red and green respectively. (I) GSEA plots of LSC and myeloid signature enrichments in AML. (J) Enrichment map of pathways significantly (FDR<0.1) changed in human AML following ELAVL1 knockdown with borders demarcating concordance/discordance with enrichments from below-median expressors of ELAVL1 from the BeatAML data set.